Onxeo divests two non-core products in oral pathologies to Vectans Pharma. Onxeo S.A., a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced the sale of two historical products Sitavig® and Loramyc® to Vectans Pharma, a private pharmaceutical company which develops and markets innovative…
JSR Life Sciences to Acquire Cell Line Developer Selexis SA
JSR Life Sciences agrees to acquire pioneering cell line developer Selexis SA and integrate Selexis with KBI Biopharma, Inc. JSR Life Sciences (JLS) announced that JSR Corporation has agreed to acquire Selexis SA, a life sciences company and global leader in mammalian (suspension-adapted CHO-K1) cell-line generation technologies. Once completed, this transaction will mark the second major…
Cell Therapy Company Joins Forces with Biotech in New Transplantation Research Alliance
Genentech’s Cancer Immunotherapy Gains FDA Priority Review for Bladder Cancer
FDA grants Genentech’s cancer immunotherapy TECENTRIQ® (atezolizumab) priority review in additional type of advanced bladder cancer. Genentech, a member of the Roche Group, announced that the U.S. FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are…
ECCO Recommends Switching from Infliximab to Biosimilar for IBD
New statement from European Crohn’s and Colitis Organisation supports switching to biosimilar from reference product in inflammatory bowel disease. Celltrion Healthcare welcomes the publication of the latest position paper from the European Crohn’s and Colitis Organisation (ECCO) on the use of biosimilars for inflammatory bowel disease (IBD), which supports switching from reference infliximab to biosimilar…
CA Prop. 61: Lies, Confusion, Fear Mongering?
CA Prop. 61: Despite record $126M, pharma offers no fix to public on drug pricing; just lies, confusion, fear mongering. As the final days to next Tuesday’s election in California play out, backers of Proposition 61, the California Drug Price Relief Act, who have faced fierce opposition from the pharmaceutical industry working to defeat the measure, continue their…
Evotec Announces Its Intent to Acquire Cyprotex Plc
Sunovion Pharmaceuticals Completes Acquisition of Cynapsus Therapeutics
Sunovion Pharmaceuticals Inc. and Cynapsus Therapeutics Inc. announced that Sunovion has completed, through its wholly owned subsidiary, Sunovion CNS Development Canada ULC, the previously announced acquisition of Cynapsus. The acquisition is aligned with Sunovion’s global strategy to expand and diversify its portfolio in key therapeutic areas, including neurology. Sunovion intends to advance the clinical development program for…
Patheon Announces the Retirement of Stuart Grant
Patheon N.V., a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, today announced that its executive vice president and chief financial officer, Stuart Grant, plans to retire in 2017. Grant will remain in his current role until a successor has been appointed and a transition has been completed.…
Teva Announces Sale of UK and Ireland Actavis Assets and Operations
Teva Pharmaceutical Industries Ltd. announced that it has agreed to sell assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited (a subsidiary of Intas Pharmaceuticals Ltd) for an agreed value of GBP 603 million, subject to final approval from the European Commission. The divestment of certain specified Actavis Generics assets…